98%
921
2 minutes
20
Williams-Beuren syndrome (WBS) is a neurodevelopmental disorder caused by a heterozygous deletion of 26-28 genes at chromosome band 7q11.23. The complete deletion (CD) mouse model mimics the most common deletion found in WBS patients and recapitulates most neurologic features of the disorder along with some cardiovascular manifestations leading to significant cardiac hypertrophy with increased cardiomyocytes' size. Epigallocatechin-3-gallate (EGCG), the most abundant catechin found in green tea, has been associated with potential health benefits, both on cognition and cardiovascular phenotypes, through several mechanisms. We aimed to investigate the effects of green tea extracts on WBS-related phenotypes through a phase I clinical trial in mice. After feeding CD animals with green tea extracts dissolved in the drinking water, starting at three different time periods (prenatal, youth and adulthood), a set of behavioral tests and several anatomical, histological and molecular analyses were performed. Treatment resulted to be effective in the reduction of cardiac hypertrophy and was also able to ameliorate short-term memory deficits of CD mice. Taken together, these results suggest that EGCG might have a therapeutic and/or preventive role in the management of WBS.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858783 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194476 | PLOS |
Int J Cardiol
September 2025
Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197 Rome, Italy. Electronic address:
Introduction: Endurance athletes are expected to present a cardiac remodeling characterized by eccentric hypertrophy. Differentiation from underlying cardiomyopathy mimicking a similar cardiac remodeling may be challenging. Myocardial work indexes (MWI) have been shown to be useful in distinguishing between physiological adaption and pathological changes in the athletes' heart.
View Article and Find Full Text PDFJ Mol Cell Cardiol
September 2025
Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Selective therapeutic targeting of cardiomyocytes (CMs) and non-myocytes (NMs) within the heart is an active field of research. The success of those novel therapeutic strategies is linked to the ability to accurately assess uptake and gene delivery efficiencies in clinically relevant animal models. Nevertheless, quantification at the single cell level remains a significant challenge.
View Article and Find Full Text PDFJACC Case Rep
September 2025
Division of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Background: Lipomatous hypertrophy of the interatrial septum (LHIS) is a benign cardiac lesion characterized by excessive fat accumulation in the interatrial septum, often sparing the fossa ovalis. Although typically asymptomatic, severe cases may lead to hemodynamic compromise.
Cases Summary: We report 2 cases of exuberant symptomatic LHIS requiring surgical intervention.
Redox Biol
September 2025
Department of Cardiology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 201620, China. Electronic address:
Pathological cardiac hypertrophy, driven by mitochondrial dysfunction and maladaptive remodeling, remains a therapeutic challenge. This study explores the cardioprotective properties of tectorigenin (Tec) in the context of transverse aortic constriction (TAC)-induced hypertrophy, focusing on mitochondrial homeostasis. In animal models, administration of Tec improved survival rates, reduced cardiac dysfunction, and decreased hypertrophy and fibrosis in TAC mice, while preserving mitochondrial function.
View Article and Find Full Text PDFFam Pract
August 2025
Faculty of Medicine, University of Porto, Porto 4200-319, Portugal.
Background: Primary healthcare centers (PHC) play a pivotal role in the first-line management of patients with diabetes and hypertension, major risk factors for heart failure (HF) development. Point-of-care cardiac ultrasound (POCUS), integrated as an extension of the physical examination, holds significant potential to enhance diagnostic accuracy and clinical management in this setting.
Objectives: Evaluate the impact of POCUS on clinical decision-making in patients with HF and at risk of developing HF in PHC and compare POCUS findings with clinical assessment alone, conventional echocardiography, and electrocardiogram results.